New combinations and immunotherapies for melanoma: latest evidence and clinical utility

di Menzies, Alexander M., Long, Georgina V.
Pubblicazione 2013

Dabrafenib and its potential for the treatment of metastatic melanoma

di Menzies, Alexander M, Long, Georgina V, Murali, Rajmohan
Pubblicazione 2012

Biology and treatment of BRAF mutant metastatic melanoma

di Kong, Benjamin Y, Carlino, Matteo S, Menzies, Alexander M
Pubblicato in Melanoma Manag (2016)

Immune checkpoint inhibitors in challenging populations

di Johnson, Douglas B., Sullivan, Ryan J., Menzies, Alexander M.
Pubblicato in Cancer (2017)

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

di Menzies, Alexander M, Yeh, Iwei, Botton, Thomas, Bastian, Boris C., Scolyer, Richard A, Long, Georgina V
Pubblicato in Pigment Cell Melanoma Res (2015)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors

di Muir, Christopher Alan, Menzies, Alexander M, Clifton-Bligh, Roderick John, Long, Georgina V, Scolyer, Richard A, Tsang, Venessa
Pubblicato in J Endocr Soc (2021)

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

di Hultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan, Wong, Muh Geot
Pubblicato in BMC Nephrol (2020)

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors

di Ziemys, Arturas, Kim, Michelle, Menzies, Alexander M., Wilmott, James S., Long, Georgina V., Scolyer, Richard A., Kwong, Larry, Holder, Ashley, Boland, Genevieve
Pubblicato in Front Oncol (2020)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

di Menzies, Alexander M., Haydu, Lauren E., Carlino, Matteo S., Azer, Mary W. F., Carr, Peter J. A., Kefford, Richard F., Long, Georgina V.
Pubblicazione 2014

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

di Carlino, Matteo S, Vanella, Vito, Girgis, Christina, Giannarelli, Diana, Guminski, Alex, Festino, Lucia, Kefford, Richard F, Menzies, Alexander M, Long, Georgina V, Ascierto, Paolo A
Pubblicato in Br J Cancer (2016)

Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”

di Tsang, Venessa H M, McGrath, Rachel T, Clifton-Bligh, Roderick J, Scolyer, Richard A, Jakrot, Valerie, Guminski, Alexander D, Long, Georgina V, Menzies, Alexander M
Pubblicato in J Clin Endocrinol Metab (2020)

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

di Lee, Jenny H., Long, Georgina V., Menzies, Alexander M., Lo, Serigne, Guminski, Alexander, Whitbourne, Kataraina, Peranec, Michelle, Scolyer, Richard, Kefford, Richard F., Rizos, Helen, Carlino, Matteo S.
Pubblicato in JAMA Oncol (2018)

Current management of patients with melanoma who are found to be sentinel node‐positive

di Nijhuis, Amanda A. G., Spillane, Andrew J., Stretch, Jonathan R., Saw, Robyn P. M., Menzies, Alexander M., Uren, Roger F., Thompson, John F., Nieweg, Omgo E.
Pubblicato in ANZ J Surg (2019)

Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol

di Dieng, Mbathio, Khanna, Nikita, Nguyen, Mai Thi Hoang, Turner, Robin, Lord, Sarah J, Menzies, Alexander M, Allen, Jay, Saw, Robyn, Nieweg, Omgo E, Thompson, John, Morton, Rachael L
Pubblicato in BMJ Open (2020)

Tolerance and Efficacy of BRAF Plus MEK Inhibition in Patients With Melanoma Who Previously Have Received Programmed Cell Death Protein 1-Based Therapy

di Saab, Karim R., Mooradian, Meghan, Wang, Daniel Y., Chon, Jeewon, Xia, Cathy Y., Bialczak, Angelica, Abbate, Kelly T., Menzies, Alexander M., Johnson, Douglas B., Sullivan, Ryan J., Shoushtari, Alexander N.
Pubblicato in Cancer (2018)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

di Nahar, Kazi J, Rawson, Robert V, Ahmed, Tasnia, Tattersall, Stephen, Sandanayake, Neomal, Kiely, Christopher J, Lo, Serigne, Carlino, Matteo, Palendira, Umaimainthan, Scolyer, Richard A, Long, Georgina V, Menzies, Alexander M
Pubblicato in J Immunother Cancer (2020)

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors

di Lezcano, Cecilia, Lee, Chung-Wei, Larson, Allison R., Menzies, Alexander M., Kefford, Richard F., Thompson, John F., Mihm, Martin C., Ogino, Shuji, Long, Georgina V., Scolyer, Richard A., Murphy, George F.
Pubblicazione 2014

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

di Pupo, Gulietta M., Boyd, Suzanah C., Fung, Carina, Carlino, Matteo S., Menzies, Alexander M., Pedersen, Bernadette, Johansson, Peter, Hayward, Nicholas K., Kefford, Richard F., Scolyer, Richard A., Long, Georgina V., Rizos, Helen
Pubblicato in Biomark Res (2017)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

di Lim, Su Yin, Lee, Jenny H., Welsh, Sarah J., Ahn, Seong Beom, Breen, Edmond, Khan, Alamgir, Carlino, Matteo S., Menzies, Alexander M., Kefford, Richard F., Scolyer, Richard A., Long, Georgina V., Rizos, Helen
Pubblicato in Biomark Res (2017)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

di Gide, Tuba N., Silva, Ines P., Quek, Camelia, Ahmed, Tasnia, Menzies, Alexander M., Carlino, Matteo S., Saw, Robyn P.M., Thompson, John F., Batten, Marcel, Long, Georgina V., Scolyer, Richard A., Wilmott, James S.
Pubblicato in Oncoimmunology (2019)